Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15533598 | 0.85 | EPHX2 (0.52) | EPHX2HTR2CPLD1HTR1ASLC6A2 | |
| SCHEMBL15533646 | 0.82 | EPHX2 (0.50) | EPHX2HTR2CPLD1HTR1ASLC6A2 | |
| SCHEMBL1026306 | 0.81 | CYP2C19 (0.57) | EPHX2HTR1ASLC6A2ALDH1A1 | |
| SCHEMBL31652008 | 0.81 | EPHX2 (0.49) | EPHX2HTR2CHTR1ASLC6A2 | |
| SCHEMBL3882059 | 0.81 | EPHX2 (0.49) | EPHX2HTR2CPLD1HTR1ASLC6A2 | |
| SCHEMBL31651713 | 0.81 | EPHX2 (0.55) | EPHX2HTR2CPLD1HTR1ASLC6A2 | |
| SCHEMBL31651660 | 0.81 | EPHX2 (0.62) | EPHX2HTR2CPLD1HTR1ASLC6A2 | |
| SCHEMBL4317786 | 0.80 | MAPT (0.49) | EPHX2HTR2CPLD1HTR1ASLC6A2 | |
| SCHEMBL12251269 | 0.80 | HTR1A (0.53) | EPHX2HTR2CPLD1HTR1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL1969103 | 0.80 | LMNA (0.58) | EPHX2HTR1ASLC6A2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | EPHX2 2525/4885HTR2C 3952/4885PLD1 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.